Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery Market Report 2026

The deoxyribonucleic acid (dna) sequencing in drug discovery market size has grown rapidly in recent years. It will grow from $8.46 billion in 2025 to $9.49 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing investment in genomic research, expansion of pharmaceutical R&D pipelines, availability of high-throughput sequencing platforms, growing focus on personalized medicine, advances in sequencing accuracy and speed.

The deoxyribonucleic acid (dna) sequencing in drug discovery market size is expected to see rapid growth in the next few years. It will grow to $15.22 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to increasing adoption of AI-driven genomic analysis, rising demand for targeted therapeutics, expansion of pharmacogenomics applications, growing use of sequencing in early-stage drug screening, increasing collaboration between pharma and biotech firms. Major trends in the forecast period include increasing use of next-generation sequencing in target identification, rising adoption of single-cell sequencing approaches, growing integration of bioinformatics in drug discovery, expansion of precision medicine research programs, enhanced focus on biomarker-driven drug development.

The rising demand for personalized medicine is anticipated to drive the growth of deoxyribonucleic acid (DNA) sequencing in the drug discovery market in the coming years. Personalized medicine refers to a medical approach that customizes disease prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and environmental factors. The rising demand for personalized medicine is primarily due to advances in genomics and molecular diagnostics, which enable precise identification of genetic and molecular differences among individuals, allowing for treatments that are more effective and have fewer side effects. Deoxyribonucleic acid (DNA) sequencing supports personalized medicine by detecting patient-specific genetic variations, facilitating the development of targeted therapies, optimized drug selection, and improved treatment efficacy with reduced adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is driving the growth of deoxyribonucleic acid (DNA) sequencing in the drug discovery market.

Companies operating in the deoxyribonucleic acid (DNA) sequencing in the drug discovery market are focusing on developing advanced solutions, such as high-resolution DNA methylation sequencing assays, to accelerate biomarker discovery and precision drug development. High-resolution DNA methylation sequencing assays are sophisticated genomic methods that accurately profile DNA methylation at single-base or near single-base resolution across the genome, allowing in-depth evaluation of epigenetic changes to control gene activity, aiding precise understanding of disease biology and identification of potential drug targets. For example, in April 2025, EpiCypher Inc., a US-based epigenetics company, launched CUTANA mCUT&RUN and Multiomic CUT&RUN, two innovative DNA methylation sequencing assays designed to provide high-resolution methylation profiling with significantly lower sequencing costs and sample input requirements. These assays enable researchers to simultaneously analyze DNA methylation and chromatin features, offering deeper multiomic insights into gene regulation mechanisms. These assay advancements support faster and more cost-effective target identification and validation, thereby accelerating drug discovery and development.

In May 2025, Mapmygenome India Pvt. Ltd., an India-based provider of AI-driven genomics and personalized health solutions, acquired Microbiome Insights for an undisclosed amount. Through this acquisition, Mapmygenome seeks to expand its scientific and sequencing capabilities in microbiome research, accelerate its entry into the North American market, and broaden its integrated genomics and microbiome service offerings. Microbiome Insights Inc. is a Canada-based company offering deoxyribonucleic acid (DNA) sequencing services tailored for drug discovery, development, and clinical trials in the pharmaceutical and biotechnology sectors.

Major companies operating in the deoxyribonucleic acid (dna) sequencing in drug discovery market are Thermo Fisher Scientific Inc., Eurofins Genomics GmbH, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Genomics, Azenta Life Sciences, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Element Biosciences Inc., Macrogen Inc., Ultima Genomics Inc., SOPHiA GENETICS SA, ProPhase Labs Inc., Singular Genomics Systems Inc., Psomagen Inc., and QitanTech Co Ltd.

Tariffs are impacting the DNA sequencing in drug discovery market by increasing costs of imported sequencing instruments, reagents, flow cells, and data processing hardware. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported high-end sequencing platforms, while Asia-Pacific faces cost pressure on consumables supply chains. These tariffs are raising research costs and extending project timelines. However, they are also driving local manufacturing of sequencing consumables, regional supplier diversification, and increased investment in domestic genomics infrastructure.

The deoxyribonucleic acid (dna) sequencing in drug discovery market research report is one of a series of new reports that provides deoxyribonucleic acid (dna) sequencing in drug discovery market statistics, including deoxyribonucleic acid (dna) sequencing in drug discovery industry global market size, regional shares, competitors with a deoxyribonucleic acid (dna) sequencing in drug discovery market share, detailed deoxyribonucleic acid (dna) sequencing in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (dna) sequencing in drug discovery industry. This deoxyribonucleic acid (dna) sequencing in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deoxyribonucleic acid (DNA) sequencing in drug discovery refers to the process of identifying the exact sequence of nucleotides in genetic material to analyze disease mechanisms at the molecular level. It allows researchers to detect genetic variations, biomarkers, and therapeutic targets that affect disease progression and treatment response. Through detailed genomic insights, DNA sequencing enables the development of more targeted, effective, and personalized drug candidates.

The principal product types of deoxyribonucleic acid (DNA) sequencing in drug discovery include instruments and consumables. Instruments refer to laboratory equipment used to conduct sequencing experiments and analyze genetic material for drug discovery purposes. Sequencing workflows involve sample preparation and sequencing processes. The technology types comprise Sanger sequencing and next-generation sequencing. Applications include drug discovery and pharmacogenomics, and the end users are pharmaceutical companies and biotechnology firms.

The deoxyribonucleic acid (DNA) sequencing in the drug discovery market includes revenues earned by entities through next-generation sequencing services, whole genome sequencing services, whole exome sequencing services, targeted sequencing services, Sanger sequencing services, and single-cell sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.